Home » Stocks » Eucrates Biomedical Acquisition

Eucrates Biomedical Acquisition Corp. (EUCR)

Eucrates Biomedical Acquisition will go public soon, but the exact IPO date is still unknown.
Stock Price: $10.00
Confirmed IPO price

Stock Price Chart

Key Info

Market Cap 128.50M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 12.85M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 128.50M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.85M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Eucrates Biomedical Acquisition Corp.
Country United States
CEO Parag Saxena

Stock Information

Ticker Symbol EUCR
Stock Exchange NASDAQ
Industry Blank Checks / SPAC
Unique Identifier NASDAQ: EUCR
IPO Date Pending

Description

Eucrates Biomedical Acquisition is a newly organized blank check company incorporated on August 21, 2020 as a British Virgin Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that complement our management team’s background, and capitalize on the ability of our management team to identify and acquire a business, focusing on the biomedical or healthcare-related industries. In particular, we will target North American and European healthcare companies with the potential to drive transformational change through the convergence of biomedicine and data science, areas in which our management team and Board of Directors have extensive operating, investing and transactional experience.